Aliases:This biomarker is also known as:
- Apolipoprotein A1,
- apolipoprotein A-I,
- Apolipoprotein A-I,
APOA1, a secreted protein belonging to the apolipoprotein A1/A4/E family, participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, APOA1 activates spermatozoa motility. This protein is a major protein of plasma HDL and is also found in chylomicrons. It is synthesized in the liver and small intestine. Defects in APOA1 are a cause of several diseases: 1) high density lipoprotein deficiency type 2 (HDLD2), also known as familial hypoalphalipoproteinemia, for which inheritance is autosomal dominant; 2) the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1), also known as analphalipoproteinemia or Tangier disease (TGD), a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness; 3) amyloid polyneuropathy-nephropathy Iowa type (AMYLIOWA), also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III, a hereditary generalized amyloidosis due to deposition of amyloid mainly constituted by apolipoprotein A1; 4) amyloidosis type 8 (AMYL8), also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis, a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
In laboratory testing, APOA1, in a panel (including transthyretin, transferrin, and CA125) has been shown to be a highly sensitive (96%) predictor of early stage ovarian cancer and endometrial cancer.
Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. APOA1 alone was not a strong predictor.
No associated publications found.